Ashwani Khemka, Managing Director of Sanjivani Paranteral Limited, has disclosed another acquisition of additional equity shares in the company, further increasing his shareholding percentage as a promoter. The latest disclosure was made pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Recent Share Acquisition Details

The latest acquisition involved 3,640 equity shares purchased through open market transactions on March 30, 2026. This represents 0.03% of the company's total share capital.

Updated Shareholding Position

Following this latest acquisition, Khemka's total shareholding in Sanjivani Paranteral Limited has increased to 29.60%. This follows his previous acquisition of 6,451 shares on March 27, 2026, which had increased his holding from 29.51% to 29.57%.

Company Capital Structure

Sanjivani Paranteral Limited's equity share capital structure remained unchanged following this transaction. The company maintains its existing capital base with no dilution or expansion.

Regulatory Compliance

The disclosure was filed with BSE Limited on March 31, 2026, where Sanjivani Paranteral Limited is listed under scrip code 531569. Khemka, holding DIN 00337118, submitted the required documentation as per SEBI regulations for substantial acquisition disclosures. The filing confirms his continued status as a promoter of the company and ensures transparency in shareholding changes above the prescribed thresholds.

Sanjivani Paranteral Limited has released the official transcript of its Q3FY26 earnings call held on February 16, 2026, providing detailed insights into the company's strong financial performance and future growth strategy. The Mumbai-headquartered pharmaceutical company disclosed the transcript under Regulation 46 of the SEBI Listing Regulations.

Earnings Call Disclosure and Compliance

The company informed BSE Limited on February 18, 2026, about the availability of the earnings call transcript on its website. Company Secretary Cum Compliance Officer Ravikumar Bogam signed the disclosure, emphasizing regulatory compliance under SEBI guidelines.

Strong Q3FY26 Financial Performance

The earnings call revealed impressive standalone financial results for Q3FY26. Revenue from operations reached Rs. 20.9 crores, marking a substantial 20.2% year-over-year growth. The company achieved significant margin expansion with EBITDA growing 36% year-on-year to Rs. 3.9 crores.

Segment-wise Business Performance

The company's diversified portfolio showed mixed performance across segments. Injectable revenues declined 9.7% year-on-year to Rs. 11.7 crores, while oral revenues surged 153.3% to Rs. 8.6 crores. The nutraceutical segment contributed Rs. 0.56 crores during the quarter.

SPL Infusion Integration Success

A key milestone was achieved with SPL Infusion Private Limited contributing Rs. 1.2 crores to consolidated revenues for the first time. The Pune facility is currently operating at 20-25% capacity utilization and is expected to reach 40-50% utilization by FY27.

Management Guidance and Growth Strategy

During the earnings call, management provided ambitious growth targets for the coming years. The base business is projected to reach Rs. 90 crores by FY27, while SPL Infusion is expected to contribute Rs. 60-65 crores. For FY26, the company targets Rs. 72-75 crores from core operations.

Executive Director Srivardhan Khemka highlighted the company's transition from a single-engine business to a multi-vertical growth platform, with injectables remaining the primary growth driver. The company plans to expand its product portfolio to 23-24 products at the Pune facility, compared to competitors' 12-14 products.

Regulatory Compliance and Future Outlook

Management announced that all company plants are compliant with the revised Schedule M by the FDA, positioning them among only 20-30% of plants in India meeting these stringent requirements. A WHO inspection for the Pune plant is scheduled for March 2026, which will enable regulatory approvals in various export markets.

The company maintains a cautious but optimistic outlook, expecting accelerated growth from Q2-Q3 of FY27 as new product approvals and market registrations materialize across key export territories in Africa and other emerging markets.